

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~struckthrough~~ and additions are underlined.

Listing of Claims:

1. (Currently amended) A composition comprising ~~annatto extract and at least one~~
~~ingredient selected from the group consisting of tocol containing material and non-tocol~~
~~containing material, wherein greater than 60% of the tocotols are tocotrienols~~ an oily byproduct of
Bixa orellana seed containing a tocotrienol where the ratio of delta-tocotrienol to gamma-
tocotrienol is between 1:25 to 25:1.

2-24. (Canceled)

25. (Currently amended) ~~A~~The composition of Claim 1, further comprising ~~annatto extract~~
~~and~~ at least one ingredient selected from the group consisting of phytosterols, oryzanols,
policosanols, pentathine, red yeast rice (*Monascus*), oat bran, garlic, gugul lipids, chitosan, soy
protein (e.g., oligo- and poly-peptides, hydrolysates), CoQ10, carnitine, magnesium, calcium, D-
tyroxine, fibers (insoluble and soluble types, including beta-glucans), omega-3s (DHAs and
EPAs, alpha linoleic acid), lecithin, banaba extract (including corosolic acid), lipoic acids (all
isomeric forms), chromium (all compounded forms), and B vitamins (including niacin).

26. (Withdrawn-Previously presented) A method to produce a beneficial effect comprising
administering the composition of Claim 1 to a mammal in need of a beneficial effect.

27. (Canceled)

28. (Withdrawn-Previously presented) The method of Claim 26, where the beneficial effect
is a decrease in blood levels of triglycerides.

29. (Withdrawn-Currently amended) The method of Claim 28, where the beneficial effect of the decrease in blood levels of triglycerides is ~~at least one selected from the group consisting of reversal of insulin resistance, metabolic syndrome, prediabetes, diabetes and diabetes-related cardiovascular disease.~~

30. (Withdrawn-Previously presented) The method of Claim 26, where the beneficial effect treats a malady effecting the central nervous system.

31-36. (Canceled)

37. (New) The composition of Claim 1, where the ratio of delta-tocotrienol to gamma-tocotrienol is between 1:10 to 10:1.

38. (New) The composition of Claim 37, where the ratio of delta-tocotrienol to gamma-tocotrienol is 1:1.

39. (New) A composition comprising an oily byproduct extract of *Bixa orellana* seed and a natural extract where the level of tocopherol is $\leq 50\%$.

40. (New) The composition of Claim 39 where the level of tocopherol is $\leq 20\%$.

41. (New) The composition of Claim 40 where the level of tocopherol is $\leq 1\%$.

42. (New) The composition of Claim 39 where the natural extract is selected from the group consisting of a vegetable oil of rice bran, palm, cranberry seed, and litchi seed.

43. (New) The composition of Claim 39 where the tocopherol comprises alpha-tocopherol.

44. (New) The composition of Claim 43 where alpha-tocopherol comprises $\leq 50\%$ of the tocopherols in the composition.

45. (New) The composition of Claim 44 where alpha-tocopherol comprises $\leq 25\%$ of the tocopherols in the composition.
46. (New) The composition of Claim 45 where alpha-tocopherol comprises $\leq 1\%$ of the tocopherols in the composition.
47. (New) A composition of an oily byproduct extract of *Bixa orellana* seed and a natural extract where delta-tocotrienol and gamma-tocotrienol comprise $\geq 50\%$ of the tocotrienols in the composition.
48. (New) The composition of Claim 47 where delta-tocotrienol comprises $\geq 50\%$ of the tocotrienols in the composition.
49. (New) A composition of an oily byproduct extract of *Bixa orellana* seed and a natural extract where C5 unsubstituted tocotrienols are $\geq 60\%$, and tocopherols are $\leq 15\%$.
50. (New) The composition of Claim 49 where the C5 unsubstituted tocotrienols are $\geq 80\%$ and $\leq 5\%$ tocopherols.